Storia in 2 fonti

Generic semaglutide race hinges on API supply as China leads: Goldman Sachs

The big unknown is whether CDMO capacity built for branded drugs gets diverted to generics, and whether SPPS can scale fast enough to meet a market Goldman models at ~99,000 kg of peptide API by 2030

Raccontata da

thehindubusinessline.com

economictimes.indiatimes.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

thehindubusinessline.comStai leggendo5 g fa

Generic semaglutide race hinges on API supply as China leads: Goldman Sachs

Goldman Sachs: semaglutide generic launch post-2027 constrained by peptide API capacity (~99k kg by 2030); China dominates synthetic supply. API capacity and Chinese sourcing become bottlenecks; supply-chain resilience, not just R&D, shapes biotech competitiveness.

originale

economictimes.indiatimes.com4 g fa

India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide sales

India's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moderating. Doctors note that physician training and patient education are now…

Timeline cronologica

domenica 7 giugno 2026·thehindubusinessline.com
Generic semaglutide race hinges on API supply as China leads: Goldman Sachs
The big unknown is whether CDMO capacity built for branded drugs gets diverted to generics, and whether SPPS can scale fast enough to meet a market Goldman models at ~99,000 kg of…
martedì 9 giugno 2026·economictimes.indiatimes.com
India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide sales
India's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moderating. Doctors note that physician…